| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-12-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-14-2025 | 03-31-2025 | 10-Q | |
| 3 | 04-15-2025 | 12-31-2024 | 10-K | |
| 4 | 11-14-2024 | 09-30-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.
Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safet...
D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cance...
D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.
Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety...
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today an...
